Alyeska Investment Group L.P. Decreases Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Alyeska Investment Group L.P. trimmed its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 89.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 24,997 shares of the biotechnology company’s stock after selling 210,243 shares during the quarter. Alyeska Investment Group L.P.’s holdings in Sarepta Therapeutics were worth $3,039,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Tidal Investments LLC grew its holdings in Sarepta Therapeutics by 91.2% during the 3rd quarter. Tidal Investments LLC now owns 5,634 shares of the biotechnology company’s stock valued at $704,000 after purchasing an additional 2,688 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Sarepta Therapeutics by 27.7% during the fourth quarter. GAMMA Investing LLC now owns 854 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 185 shares during the period. Everence Capital Management Inc. bought a new position in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $344,000. Nordea Investment Management AB lifted its stake in shares of Sarepta Therapeutics by 19.1% during the 4th quarter. Nordea Investment Management AB now owns 67,546 shares of the biotechnology company’s stock worth $8,228,000 after acquiring an additional 10,815 shares during the last quarter. Finally, ORG Partners LLC lifted its stake in shares of Sarepta Therapeutics by 17.6% during the 4th quarter. ORG Partners LLC now owns 2,000 shares of the biotechnology company’s stock worth $243,000 after acquiring an additional 300 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 7.70% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research firms have weighed in on SRPT. Needham & Company LLC reduced their target price on Sarepta Therapeutics from $202.00 to $183.00 and set a “buy” rating on the stock in a research note on Thursday, April 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $163.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating for the company in a research report on Wednesday, March 19th. HC Wainwright reaffirmed a “neutral” rating and set a $75.00 target price on shares of Sarepta Therapeutics in a research report on Wednesday, April 16th. Finally, Wells Fargo & Company began coverage on Sarepta Therapeutics in a report on Friday, April 11th. They issued an “overweight” rating and a $115.00 price target for the company. Six analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $157.95.

Sarepta Therapeutics Stock Down 26.6 %

NASDAQ:SRPT opened at $46.75 on Wednesday. Sarepta Therapeutics, Inc. has a fifty-two week low of $37.02 and a fifty-two week high of $173.25. The stock has a market capitalization of $4.59 billion, a P/E ratio of 37.40 and a beta of 0.85. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The company’s 50-day simple moving average is $70.87 and its 200-day simple moving average is $102.57.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.